Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. Common Stock（LXEO）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · LXEO · 截至 2025年9月30日
股东结构概览
112
机构持有人数
▲ 21 vs Q2
$327.72M
机构持仓总市值
▲ $157.72M vs Q2
78.52M
总流通股
freeFloat 60.50%
49.36M
13F 申报持股数
▲ 7.09M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
LXEO 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
JANUS HENDERSON GROUP PLC biological products, (no diagnostic substances) | 6.11M | 10.01% | 10.01% | $40.49B | Nov 14, 2025 | ▲ 2.42M |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. biological products, (no diagnostic substances) | 4.42M | 7.26% | 7.26% | $29.38B | Nov 14, 2025 | — held |
BALYASNY ASSET MANAGEMENT L.P. biological products, (no diagnostic substances) | 3.91M | 6.42% | 6.42% | $25.99B | Nov 14, 2025 | ▼ 95.3K |
AFFINITY ASSET ADVISORS, LLC biological products, (no diagnostic substances) | 3.87M | 6.35% | 6.35% | $25.70B | Nov 13, 2025 | ▲ 281.2K |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 3.72M | 6.10% | 6.10% | $24.69B | Nov 14, 2025 | ▲ 111.1K |
VESTAL POINT CAPITAL, LP biological products, (no diagnostic substances) | 3.25M | 5.33% | 5.33% | $21.58B | Nov 14, 2025 | ▲ 21.8K |
WOODLINE PARTNERS LP biological products, (no diagnostic substances) | 2.57M | 4.22% | 4.22% | $17.08B | Nov 14, 2025 | — held |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 2.31M | 3.79% | 3.79% | $15.36B | Nov 14, 2025 | ▼ 522.6K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.23M | 3.65% | 3.65% | $14.78B | Nov 7, 2025 | ▲ 223.4K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 2.17M | 3.56% | 3.56% | $14.42B | Nov 12, 2025 | ▲ 343.1K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
27
增持
+7.63M 股6
新建仓
首次建仓9
减持
−687.9K 股0
清仓
完全退出净股数变化（前50家）
+6.95M
+7.63M / −687.9K
净新增持仓人
+24
新建 6 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
LXEO 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
1
买入笔数
3
卖出笔数
0.33
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Otero Jose Manuel Chief Operating Officer | May 18, 2026 | Sale | 1,302 | $5.07 | $6.6K | 130.1K | Form 4 ↗ |
Townsend Richard Nolan Chief Executive Officer | May 18, 2026 | Sale | 3,342 | $5.06 | $16.9K | 336.8K | Form 4 ↗ |
Sepp-Lorenzino Laura director | Apr 28, 2026 | Award | 50,000 | $5.81 | $290.5K | 50.0K | Form 4 ↗ |
Townsend Richard Nolan Chief Executive Officer | Apr 6, 2026 | Sale | 55,000 | $5.69 | $313.1K | 340.1K | Form 4 ↗ |
Townsend Richard Nolan Chief Executive Officer | Mar 13, 2026 | Award | 2,623 | $2.64 | $6.9K | 395.1K | Form 4 ↗ |
Otero Jose Manuel Chief Operating Officer | Mar 13, 2026 | Award | 5,930 | $2.64 | $15.7K | 131.4K | Form 4 ↗ |
Otero Jose Manuel Chief Operating Officer | Feb 18, 2026 | Sale | 3,016 | $6.40 | $19.3K | 125.5K | Form 4 ↗ |
Townsend Richard Nolan Chief Executive Officer | Feb 18, 2026 | Sale | 10,173 | $6.38 | $64.9K | 392.5K | Form 4 ↗ |
Otero Jose Manuel Chief Operating Officer | Nov 18, 2025 | Sale | 721 | $9.27 | $6.7K | 63.5K | Form 4 ↗ |
Bhalla Narinder Pal Chief Medical Officer | Feb 13, 2026 | Award | 297,000 | $6.31 | $1.87M | 297.0K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Lexeo Therapeutics, Inc. Common Stock（LXEO）主要由机构投资者持有，机构持股比例约为 62.9%。公司内部人员持股约 39.50%，散户及公众持股约占剩余的 0.00%。
Lexeo Therapeutics, Inc. Common Stock 最大机构股东为 JANUS HENDERSON GROUP PLC，截至 September 30, 2025 持有约 6.11 million 股，占总流通股的 10.01%。
目前共有 112 家机构持有 LXEO 股票，合计持仓市值约 $327,717,307，数据来源为最新 SEC 13F 申报。
常见问题
LXEO ownershipLexeo Therapeutics, Inc. Common Stock（LXEO）主要由机构投资者持有，机构持股约 62.9%。最大股东为 JANUS HENDERSON GROUP PLC，持股比例 10.01%。内部人员持股约 39.50%。数据来源 SEC Form 13F，截至 September 30, 2025。